Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM4B | O94953 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.31 |
| ▸ | KDM5A | P29375 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20505096 | 0.71 | MAPT (0.44) | MAOAMAOBGAAMAPT | |
| SCHEMBL20723 | 0.71 | MAPT (0.44) | MAOAMAOBGAAMAPT | |
| SCHEMBL3956651 | 0.67 | PDE3B (0.37) | PDE3BPDE3AKDM4CKDM4AKDM4B | |
| SCHEMBL2719976 | 0.65 | CES1 (0.44) | PDE3BPDE3AMAPT | |
| SCHEMBL4753998 | 0.65 | CMA1 (0.43) | MAPT | |
| SCHEMBL4750491 | 0.65 | HTR5A (0.36) | MAPTPARP1DAO | |
| SCHEMBL9111832 | 0.65 | CYP11B1 (0.51) | PDE3BPDE3ACYP11B1CYP11B2MAPT | |
| SCHEMBL1288453 | 0.65 | CYP11B1 (0.55) | PDE3BPDE3ACYP11B1CYP11B2MAPT | |
| SCHEMBL3959190 | 0.63 | PDE3B (0.40) | PDE3BPDE3AKDM4CKDM4AKDM4B | |
| SCHEMBL29974124 | 0.62 | MAOA (0.52) | PDE3BPDE3AMAOAMAOBCDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148104-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
| US-11845760-B2 | PRMT5 inhibitors | AMGEN INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4288435-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | Amgen Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4103558-A1 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2021163344-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | PDE3B 1523/4885PDE3A 1629/4885KDM4C 1104/4885 |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PDE3B 1125/4885PDE3A 1166/4885KDM4C 104/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | PDE3B 1780/4885PDE3A 1884/4885KDM4C 1275/4885 |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PDE3B 1166/4885PDE3A 1061/4885KDM4C 195/4885 |
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PDE3B 1074/4885PDE3A 1275/4885KDM4C 163/4885 |
| US-11845760-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | PDE3B 681/4885PDE3A 822/4885KDM4C 167/4885 |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | PDE3B 613/4885PDE3A 740/4885KDM4C 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.